2024-519170-39-00RecruitingPhase 1/2
Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovarian cancer: The PROOV study - A Phase I/II clinical trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 11 Dec 2024
- Start date
- 7 Apr 2025
- Lead sponsor
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Diseases
- Ovarian cancer
- EU CT number
- 2024-519170-39-00
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 55
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Recruiting |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.